



## **2025 Formulary Changes**

**EFFECTIVE DATE: 11/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| Drug Name                          | Alternate Drugs and Tier               | Change Type                        | Change Reason                                                                                |
|------------------------------------|----------------------------------------|------------------------------------|----------------------------------------------------------------------------------------------|
| EPRONTIA 25 MG/ML<br>ORAL SOLUTION | TOPIRAMATE 25 MG/ML ORAL<br>SOLUTION-3 | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO<br>ADDITION OF NEW GENERIC<br>EQUIVALENT |

**EFFECTIVE DATE: 10/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| <b>Drug Name</b>                 | <b>Alternate Drugs and Tier</b>               | <b>Change Type</b>                            | <b>Change Reason</b>                                                                |
|----------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------|
| JYNARQUE 15 MG ORAL TABLET       | TOLVAPTAN 15 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| FYCOMPA 6 MG ORAL TABLET         | PERAMPANEL 6 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| FYCOMPA 12 MG ORAL TABLET        | PERAMPANEL 12 MG ORAL TABLET-5                | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| FYCOMPA 10 MG ORAL TABLET        | PERAMPANEL 10 MG ORAL TABLET-5                | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| FYCOMPA 8 MG ORAL TABLET         | PERAMPANEL 8 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| JYNARQUE 30 MG ORAL TABLET       | TOLVAPTAN 30 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| FYCOMPA 2 MG ORAL TABLET         | PERAMPANEL 2 MG ORAL TABLET-3                 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| ENTRESTO 97MG-103MG ORAL TABLET  | SACUBITRIL-VALSARTAN 97MG-103MG ORAL TABLET-3 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| ENTRESTO 49 MG-51MG ORAL TABLET  | SACUBITRIL-VALSARTAN 49 MG-51MG ORAL TABLET-3 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| ENTRESTO 24 MG-26MG ORAL TABLET  | SACUBITRIL-VALSARTAN 24 MG-26MG ORAL TABLET-3 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| IXCHIQ 1000 TCID INTRAMUSC. VIAL |                                               | REMOVAL DUE TO FDA MANDATED MARKET WITHDRAWAL | REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL                |
| FYCOMPA 4 MG ORAL TABLET         | PERAMPANEL 4 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC               | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |

**EFFECTIVE DATE: 09/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| <b>Drug Name</b>                | <b>Alternate Drugs and Tier</b>                         | <b>Change Type</b>              | <b>Change Reason</b>                                                                |
|---------------------------------|---------------------------------------------------------|---------------------------------|-------------------------------------------------------------------------------------|
| PROMACTA 75 MG ORAL TABLET      | ELTROMBOPAG OLAMINE 75 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| PROMACTA 50 MG ORAL TABLET      | ELTROMBOPAG OLAMINE 50 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| PROMACTA 12.5 MG ORAL TABLET    | ELTROMBOPAG OLAMINE 12.5 MG ORAL TABLET-5               | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| PROMACTA 25 MG ORAL POWD PACK   | ELTROMBOPAG OLAMINE 25 MG ORAL POWD PACK-5              | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| PROMACTA 12.5 MG ORAL POWD PACK | ELTROMBOPAG OLAMINE 12.5 MG ORAL POWD PACK-5            | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| COMPLERA 200-25-300 ORAL TABLET | EMTRICITABINE-RILPIVIRNE-TENOF 200-25-300 ORAL TABLET-5 | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| PROMACTA 25 MG ORAL TABLET      | ELTROMBOPAG OLAMINE 25 MG ORAL TABLET-5                 | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |

**EFFECTIVE DATE: 08/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| <b>Drug Name</b>                           | <b>Alternate Drugs and Tier</b>                 | <b>Change Type</b>                 | <b>Change Reason</b>                                                                      |
|--------------------------------------------|-------------------------------------------------|------------------------------------|-------------------------------------------------------------------------------------------|
| APTOM 600 MG<br>ORAL TABLET                | ESLICARBAZEPINE ACETATE 600 MG<br>ORAL TABLET-5 | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| APTOM 400 MG<br>ORAL TABLET                | ESLICARBAZEPINE ACETATE 400 MG<br>ORAL TABLET-5 | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| APTOM 800 MG<br>ORAL TABLET                | ESLICARBAZEPINE ACETATE 800 MG<br>ORAL TABLET-5 | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| JYNARQUE 30 MG-<br>15MG ORAL TABLET<br>SEQ | TOLVAPTAN 30 MG-15MG ORAL TABLET<br>SEQ-5       | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| JYNARQUE 90 MG-<br>30MG ORAL TABLET<br>SEQ | TOLVAPTAN 90 MG-30MG ORAL TABLET<br>SEQ-5       | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| JYNARQUE 60 MG-<br>30MG ORAL TABLET<br>SEQ | TOLVAPTAN 60 MG-30MG ORAL TABLET<br>SEQ-5       | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| JYNARQUE 15 MG-<br>15MG ORAL TABLET<br>SEQ | TOLVAPTAN 15 MG-15MG ORAL TABLET<br>SEQ-5       | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| JYNARQUE 45 MG-<br>15MG ORAL TABLET<br>SEQ | TOLVAPTAN 45 MG-15MG ORAL TABLET<br>SEQ-5       | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |
| APTOM 200 MG<br>ORAL TABLET                | ESLICARBAZEPINE ACETATE 200 MG<br>ORAL TABLET-5 | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |

**EFFECTIVE DATE: 06/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| <b>Drug Name</b>                   | <b>Alternate Drugs and Tier</b>             | <b>Change Type</b>                 | <b>Change Reason</b>                                                                      |
|------------------------------------|---------------------------------------------|------------------------------------|-------------------------------------------------------------------------------------------|
| PURIXAN 20 MG/ML<br>ORAL ORAL SUSP | MERCAPTOPURINE 20 MG/ML ORAL<br>ORAL SUSP-5 | BRAND DELETION, ADD<br>FRF GENERIC | REMOVAL OF BRAND NAME DRUG<br>FROM FORMULARY DUE TO ADDITION<br>OF NEW GENERIC EQUIVALENT |

**EFFECTIVE DATE: 04/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| <b>Drug Name</b>                  | <b>Alternate Drugs and Tier</b> | <b>Change Type</b>              | <b>Change Reason</b>                                                                |
|-----------------------------------|---------------------------------|---------------------------------|-------------------------------------------------------------------------------------|
| TRUSELTIQ 75 MG/DAY ORAL CAPSULE  |                                 | DELETION OF DRUG FROM FORMULARY | NO LONGER FDA APPROVED                                                              |
| TRUSELTIQ 50 MG/DAY ORAL CAPSULE  |                                 | DELETION OF DRUG FROM FORMULARY | NO LONGER FDA APPROVED                                                              |
| TRUSELTIQ 100 MG/DAY ORAL CAPSULE |                                 | DELETION OF DRUG FROM FORMULARY | NO LONGER FDA APPROVED                                                              |
| MESNEX 400 MG ORAL TABLET         | MESNA 400 MG ORAL TABLET-5      | BRAND DELETION, ADD FRF GENERIC | REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT |
| TRUSELTIQ 125 MG/DAY ORAL CAPSULE |                                 | DELETION OF DRUG FROM FORMULARY | NO LONGER FDA APPROVED                                                              |

**EFFECTIVE DATE: 02/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

| <b>Drug Name</b>           | <b>Alternate Drugs and Tier</b> |
|----------------------------|---------------------------------|
| SPRYCEL 70 MG ORAL TABLET  | DASATINIB 70 MG ORAL TABLET-5   |
| SPRYCEL 80 MG ORAL TABLET  | DASATINIB 80 MG ORAL TABLET-5   |
| SPRYCEL 140 MG ORAL TABLET | DASATINIB 140 MG ORAL TABLET-5  |
| SPRYCEL 20 MG ORAL TABLET  | DASATINIB 20 MG ORAL TABLET-5   |
| SPRYCEL 50 MG ORAL TABLET  | DASATINIB 50 MG ORAL TABLET-5   |
| SPRYCEL 100 MG ORAL TABLET | DASATINIB 100 MG ORAL TABLET-5  |

**CHANGE TYPE**

**BRAND DELETION, ADD FRF GENERIC**

**CHANGE REASON**

**REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT**